X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
decitabine (1595) 1595
humans (1227) 1227
index medicus (933) 933
azacitidine - analogs & derivatives (894) 894
oncology (782) 782
dna methylation (738) 738
azacitidine - pharmacology (546) 546
cancer (504) 504
female (481) 481
hematology (475) 475
male (458) 458
methylation (449) 449
azacitidine (355) 355
middle aged (344) 344
azacitidine - therapeutic use (335) 335
aged (330) 330
animals (325) 325
acute myeloid-leukemia (309) 309
myelodysplastic syndromes (297) 297
cell line, tumor (295) 295
leukemia (292) 292
dna methylation - drug effects (289) 289
myelodysplastic syndrome (265) 265
5-aza-2'-deoxycytidine (260) 260
expression (243) 243
adult (234) 234
epigenetics (230) 230
treatment outcome (230) 230
antimetabolites, antineoplastic - therapeutic use (217) 217
chemotherapy (216) 216
myelodysplastic syndromes - drug therapy (212) 212
acute myeloid leukemia (206) 206
mice (201) 201
azacitidine - administration & dosage (200) 200
gene expression (178) 178
leukemia, myeloid, acute - drug therapy (178) 178
therapy (175) 175
article (173) 173
research (173) 173
aged, 80 and over (166) 166
antimetabolites, antineoplastic - pharmacology (165) 165
dna modification methylases - antagonists & inhibitors (163) 163
apoptosis (160) 160
enzyme inhibitors - pharmacology (157) 157
pharmacology & pharmacy (152) 152
prognosis (152) 152
5-aza-2'-deoxycytidine decitabine (146) 146
care and treatment (140) 140
promoter regions, genetic (140) 140
analysis (136) 136
cell biology (135) 135
dna (133) 133
biochemistry & molecular biology (129) 129
antineoplastic agents - therapeutic use (126) 126
antineoplastic agents (125) 125
gene expression regulation, neoplastic - drug effects (125) 125
5-azacytidine (122) 122
antimitotic agents (122) 122
epigenesis, genetic (122) 122
gene-expression (122) 122
antineoplastic combined chemotherapy protocols - therapeutic use (121) 121
phase-iii (120) 120
hypomethylating agents (119) 119
antineoplastic agents - pharmacology (118) 118
hematology, oncology and palliative medicine (117) 117
cells (116) 116
deoxyribonucleic acid--dna (116) 116
genetic aspects (115) 115
tumors (115) 115
genes (112) 112
older patients (112) 112
gene (108) 108
survival (108) 108
tumor cells, cultured (108) 108
mutation (103) 103
aml (102) 102
demethylation (101) 101
histone deacetylase inhibitors (100) 100
azacitidine - adverse effects (99) 99
reverse transcriptase polymerase chain reaction (99) 99
cpg islands (97) 97
health aspects (97) 97
valproic acid (97) 97
conventional care regimens (95) 95
dna methyltransferase (95) 95
dose-response relationship, drug (91) 91
medicine & public health (90) 90
hypermethylation (89) 89
leukemia, myeloid, acute - genetics (89) 89
transplantation (89) 89
hypomethylating agent (88) 88
differentiation (87) 87
myelodysplastic syndromes - genetics (87) 87
antimetabolites, antineoplastic - administration & dosage (85) 85
combination (84) 84
epigenetic therapy (84) 84
proteins (84) 84
cell proliferation - drug effects (81) 81
hemic and lymphatic diseases (80) 80
drug therapy (79) 79
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1845) 1845
Chinese (27) 27
Japanese (9) 9
Russian (6) 6
French (5) 5
German (4) 4
Polish (2) 2
Spanish (2) 2
Turkish (2) 2
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Haematologica, ISSN 0390-6078, 03/2012, Volume 97, Issue 3, pp. 393 - 401
Journal Article
Hematology, ISSN 1024-5332, 01/2019, Volume 24, Issue 1, pp. 507 - 515
Background: Approximately, one-third of adult patients with acute myeloid leukemia (AML) are refractory to initial induction chemotherapy and relapse occurs in... 
acute myeloid leukemia | molecular therapy | remission | survival | meta-analysis | Decitabine | chemotherapy | 5-aza-2′-deoxycytidine | 5-aza-2 '-deoxycytidine | MANAGEMENT | 5-AZA-2'-DEOXYCYTIDINE | VALPROIC ACID | CYTARABINE | COMBINATION | TRANSPLANTATION | THERAPY | DISEASE | HEMATOLOGY | PHASE-I | Recurrence | Decitabine - administration & dosage | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Salvage Therapy | Male | Fatigue - chemically induced | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Hyperglycemia - chemically induced | Immunotherapy | Decitabine - pharmacology | Leukemia, Myeloid, Acute - drug therapy | Antimetabolites, Antineoplastic - pharmacology | Female | Leukemia, Myeloid, Acute - therapy | Enzyme Inhibitors - adverse effects | Hematologic Diseases - chemically induced | DNA (Cytosine-5-)-Methyltransferase 1 - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Gene Expression Regulation, Leukemic - drug effects | Combined Modality Therapy | Enzyme Inhibitors - therapeutic use | Remission Induction | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | DNA Methylation - drug effects | Decitabine - therapeutic use | Decitabine - adverse effects | Gastrointestinal Diseases - chemically induced
Journal Article
International Journal of Hematology, ISSN 0925-5710, 8/2019, Volume 110, Issue 2, pp. 161 - 169
Hypomethylating agents (HMAs), azacitidine and decitabine, are standards of care in higher-risk myelodysplastic syndromes and in acute myeloid leukemia... 
Myeloid malignancies | Medicine & Public Health | Hematology | Hypomethylating agents | Chronic myelomonocytic leukemia | Oncology | Acute myeloid leukemia | Myelodysplastic syndromes | MUTATIONS PREDICT RESPONSE | LOW-DOSE DECITABINE | CYTIDINE DEAMINASE POLYMORPHISMS | ACUTE MYELOID-LEUKEMIA | RISK MYELODYSPLASTIC SYNDROMES | CONVENTIONAL CARE REGIMENS | RANDOMIZED PHASE-II | NEDD8-ACTIVATING ENZYME-INHIBITOR | HEMATOLOGY | ELDERLY-PATIENTS | Humans | Leukemia, Myelomonocytic, Chronic - genetics | Uridine - analogs & derivatives | Uridine - therapeutic use | Leukemia, Myelomonocytic, Chronic - drug therapy | Antimetabolites, Antineoplastic - administration & dosage | Decitabine - pharmacology | Leukemia, Myeloid, Acute - drug therapy | Antimetabolites, Antineoplastic - pharmacology | Myelodysplastic Syndromes - drug therapy | Azacitidine - administration & dosage | Drug Administration Schedule | Gene Expression Regulation, Leukemic - drug effects | Azacitidine - analogs & derivatives | Clinical Trials as Topic | Uridine - pharmacology | Azacitidine - pharmacology | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Uridine - administration & dosage | Myelodysplastic Syndromes - genetics | DNA Methylation - drug effects | Decitabine - therapeutic use | Drug Combinations | Azacitidine - therapeutic use | Decitabine - chemistry | Leukemia, Myeloid, Acute - genetics | Leukemia | Research institutes | Drug therapy, Combination | Myeloid leukemia | Biomarkers | Pharmacology | Pharmacokinetics | Disease control | Myelodysplastic syndrome | Neoplasms | 5-aza-2'-deoxycytidine
Journal Article
International Journal of Nanomedicine, ISSN 1176-9114, 2019, Volume 14, pp. 2091 - 2102
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 11/2019, Volume 60, Issue 13, pp. 3181 - 3187
Most patients with lower risk myelodysplastic syndromes (LR-MDS) become red blood cell (RBC) transfusion dependent at some time during their disease course.... 
azacitdine | transfusion | decitabine | MDS | HMA
Journal Article
Blood, ISSN 0006-4971, 09/2018, Volume 132, Issue 11, pp. 1125 - 1133
Journal Article
Annals of Hematology, ISSN 0939-5555, 9/2018, Volume 97, Issue 9, pp. 1689 - 1694
Journal Article
Cancer, ISSN 0008-543X, 12/2010, Volume 116, Issue 23, pp. 5420 - 5431
BACKGROUND: Recurrence is a major cause of treatment failure after allogeneic transplantation for acute myelogenous leukemia (AML) and myelodysplastic syndrome... 
recurrence | acute | leukemia | myelodysplastic | hematopoietic | syndrome | myelogenous | stem cell transplantation | DECITABINE | 5-AZA-2'-DEOXYCYTIDINE | EFFICACY | ACUTE MYELOID-LEUKEMIA | CANCER | CHEMOTHERAPY | ONCOLOGY | IMMUNOTHERAPY | MALIGNANCIES | OUTCOMES | MARROW TRANSPLANTATION
Journal Article